The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man - PubMed (original) (raw)
. 2001 Jun 1;276(22):19166-71.
doi: 10.1074/jbc.M100097200. Epub 2001 Feb 20.
Affiliations
- PMID: 11279005
- DOI: 10.1074/jbc.M100097200
Free article
The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man
M E Baldwin et al. J Biol Chem. 2001.
Free article
Abstract
Human vascular endothelial growth factor-D (VEGF-D) binds and activates VEGFR-2 and VEGFR-3, receptors expressed on vascular and lymphatic endothelial cells. As VEGFR-2 signals for angiogenesis and VEGFR-3 is thought to signal for lymphangiogenesis, it was proposed that VEGF-D stimulates growth of blood vessels and lymphatic vessels into regions of embryos and tumors. Here we report the unexpected finding that mouse VEGF-D fails to bind mouse VEGFR-2 but binds and cross-links VEGFR-3 as demonstrated by biosensor analysis with immobilized receptor domains and bioassays of VEGFR-2 and VEGFR-3 cross-linking. Mutation of amino acids in mouse VEGF-D to those in the human homologue indicated that residues important for the VEGFR-2 interaction are clustered at, or are near, the predicted receptor-binding surface. Coordinated expression of VEGF-D and VEGFR-3 in mouse embryos was detected in the developing skin where the VEGF-D gene was expressed in a layer of cells beneath the developing epidermis and VEGFR-3 was localized on a network of vessels immediately beneath the VEGF-D-positive cells. This suggests that VEGF-D and VEGFR-3 may play a role in establishing vessels of the skin by a paracrine mechanism. Our study of receptor specificity suggests that VEGF-D may have different biological functions in mouse and man.
Similar articles
- VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.
Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. Kukk E, et al. Development. 1996 Dec;122(12):3829-37. doi: 10.1242/dev.122.12.3829. Development. 1996. PMID: 9012504 - A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.
Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF. Stacker SA, et al. J Biol Chem. 1999 Dec 3;274(49):34884-92. doi: 10.1074/jbc.274.49.34884. J Biol Chem. 1999. PMID: 10574962 - Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.
Achen MG, Roufail S, Domagala T, Catimel B, Nice EC, Geleick DM, Murphy R, Scott AM, Caesar C, Makinen T, Alitalo K, Stacker SA. Achen MG, et al. Eur J Biochem. 2000 May;267(9):2505-15. doi: 10.1046/j.1432-1327.2000.01257.x. Eur J Biochem. 2000. PMID: 10785369 - Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA, Paavonen K. Partanen TA, et al. Microsc Res Tech. 2001 Oct 15;55(2):108-21. doi: 10.1002/jemt.1162. Microsc Res Tech. 2001. PMID: 11596156 Review. - Signaling pathways induced by vascular endothelial growth factor (review).
Larrivée B, Karsan A. Larrivée B, et al. Int J Mol Med. 2000 May;5(5):447-56. doi: 10.3892/ijmm.5.5.447. Int J Mol Med. 2000. PMID: 10762646 Review.
Cited by
- VEGFD/VEGFR3 signaling contributes to the dysfunction of the astrocyte IL-3/microglia IL-3Rα cross-talk and drives neuroinflammation in mouse ischemic stroke.
Wang S, Guo Y, Cao RQ, Zhu YM, Qiao SG, Du HP, Liu Y, Xu Y, Zhou XY, Sun L, Lu QX, Schoen I, Zhang HL. Wang S, et al. Acta Pharmacol Sin. 2024 Oct 30. doi: 10.1038/s41401-024-01405-6. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39478160 - VEGFD signaling balances stability and activity-dependent structural plasticity of dendrites.
Aksan B, Kenkel AK, Yan J, Sánchez Romero J, Missirlis D, Mauceri D. Aksan B, et al. Cell Mol Life Sci. 2024 Aug 19;81(1):354. doi: 10.1007/s00018-024-05357-2. Cell Mol Life Sci. 2024. PMID: 39158743 Free PMC article. - Histological and biochemical changes in lymphatic vessels after skeletal muscle injury induced by lengthening contraction in male mice.
Tamura Y, Kawashima T, Ji RC, Agata N, Itoh Y, Kawakami K. Tamura Y, et al. Physiol Rep. 2024 Feb;12(3):e15950. doi: 10.14814/phy2.15950. Physiol Rep. 2024. PMID: 38355142 Free PMC article. - Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors.
Bokhari SMZ, Hamar P. Bokhari SMZ, et al. Int J Mol Sci. 2023 Aug 28;24(17):13317. doi: 10.3390/ijms241713317. Int J Mol Sci. 2023. PMID: 37686121 Free PMC article. Review. - Adenoviral VEGF-DΔN ΔC gene therapy for myocardial ischemia.
Pajula J, Lähteenvuo J, Lähteenvuo M, Honkonen K, Halonen P, Hätinen OP, Kuivanen A, Heikkilä M, Nurro J, Hartikainen J, Ylä-Herttuala S. Pajula J, et al. Front Bioeng Biotechnol. 2022 Dec 22;10:999226. doi: 10.3389/fbioe.2022.999226. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36619378 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous